Company(ies): Astellas Pharma
Principal Therapy Area: Cancer
£195 / $340 / €245
MDV3100, an oral androgen antagonist, works using three separate mechanisms - it blocks testosterone from binding to the androgen receptor, it impedes nuclear translocation and it inhibits binding to DNA, thus slowing growth and inducing cell death in bicalutamide-resistant cancers.
As the first triple-acting oral androgen, MDV3100 has been shown in preclinical studies to provide a more complete suppression of the androgen pathway than the most-commonly used anti-androgen, bicalutamide. Preclinical data published in Science demonstrated that MDV3100 is superior to bicalutamide in each of these three actions.
Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focussing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for firstname.lastname@example.org